Relievant Medsystems completed the close of its $50 million Series G financing. Funds will support commercialization efforts for the Intracept procedure to treat vertebrogenic pain.
Relievant Medsystems’ minimally invasive Intracept procedure is reported to be the only FDA-cleared treatment for chronic vertebrogenic low back pain, using targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain. The procedure typically takes approximately one hour in an outpatient surgery center.
Based on existing data, patients usually experience minimal post-procedure pain and generally quick recovery times. Patients often feel pain relief within two weeks of being treated with the Intracept Procedure.
Relievant Medsystems completed the close of its $50 million Series G financing. Funds will support commercialization efforts for the Intracept procedure to treat vertebrogenic pain.
Relievant Medsystems’ minimally invasive Intracept procedure is reported to be the only FDA-cleared treatment for chronic vertebrogenic low back pain, using...
Relievant Medsystems completed the close of its $50 million Series G financing. Funds will support commercialization efforts for the Intracept procedure to treat vertebrogenic pain.
Relievant Medsystems’ minimally invasive Intracept procedure is reported to be the only FDA-cleared treatment for chronic vertebrogenic low back pain, using targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain. The procedure typically takes approximately one hour in an outpatient surgery center.
Based on existing data, patients usually experience minimal post-procedure pain and generally quick recovery times. Patients often feel pain relief within two weeks of being treated with the Intracept Procedure.
Copy to clipboard 
